Nuance Investments LLC Has $10.77 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Nuance Investments LLC lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 149,413 shares of the medical equipment provider's stock after selling 15,270 shares during the quarter. Nuance Investments LLC owned about 0.07% of Hologic worth $10,771,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares during the period. Brooklyn Investment Group raised its holdings in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its holdings in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in shares of Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider's stock valued at $66,000 after purchasing an additional 183 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on HOLX. Wolfe Research assumed coverage on shares of Hologic in a research note on Friday, December 13th. They set a "peer perform" rating on the stock. Raymond James reaffirmed an "outperform" rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Evercore ISI reduced their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Finally, Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Price Performance

HOLX traded down $1.00 on Friday, hitting $61.32. 1,110,999 shares of the stock were exchanged, compared to its average volume of 1,809,690. The firm has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The business has a 50-day moving average of $65.24 and a two-hundred day moving average of $73.29.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.